Navigation Links
New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
Date:10/16/2007

NORTH BRUNSWICK, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Researchers testing a vaccine based on the live bacteria Listeria, in women with advanced cervical cancer found it to be safe. The Lovaxin C vaccine being developed by Advaxis Inc. (OTC Bulletin Board: ADXS), is intended to treat cervical cancer and head and neck cancers that result from the human papilloma virus (HPV). This marked the first time the vaccine had been treated in humans.

"Our long held belief that live Listeria vaccines are safe, even in end stage cancer patients, has been confirmed with the results from our recent Phase I/II study. We have just entered the age of safe bacterial therapies," said Dr. John Rothman, VP of Clinical Development.

The immune response that Listeria generates is called "cellular" immunity, the type needed to attack cancer. Listeria is one of the strongest stimulators of cellular immunity known. "By redirecting it against specific tumor types safely, we have created a new, and potentially very effective, class of cancer therapy," says Rothman.

Advaxis reported treating fifteen patients in three dosage groups with thirty-minute 250 ml infusions of Lovaxin C at three-week intervals. Patients were observed for a total of 111 days. With the exception of two women, all patients had had either stage IVb advanced, recurrent, or progressive cervical cancer.

Every patient experienced a flu-like syndrome in the three-to-twelve hours after dosing comprised of fever, chills, nausea, and occasional vomiting, which is consistent with immune stimulation. In the lower two doses, symptoms were well tolerated and resolved with the use of over the counter analgesics and antihistamines.

Although efficacy was not a primary focus of the trial, efficacy findings were obtained. Of the seven stable patients, three had reductions in their tumor mass subsequent to treatment. While most lesions increased in size, tumor reduction was seen in a number of lesions and two tumors disappeared completely.

One patient with IVb cancer, who had failed two prior courses of chemotherapy and a course of radiation was deemed sufficiently healthy to resume chemotherapy undergo surgery after receiving the vaccine and was removed from the trial early for this purpose and currently tumor free.

"This milestone has given us the direction for the continued development Listeria-based vaccines," said Rothman. Further vaccines in development target breast, ovarian and lung cancers. For more information log on to http://www.advaxis.com.


'/>"/>
SOURCE Advaxis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016  Dynatronics Corporation (NASDAQ: DYNT ... devices and rehabilitation equipment for the physical therapy, ... Broncos, football team for winning the 2016 World ... Chairman and Chief Executive Officer.  "The Broncos have ... forward to enhancing their athletic achievements with our ...
(Date:2/8/2016)... , February 8, 2016 ... report published by Allied Market Research titled, "World ... and Forecasts, 2014-2020", estimates the world synthetic biology ... synthesis and sequencing technology segment would continue to ... software tools segment, collectively, held around half of ...
(Date:2/5/2016)... OAKS, Calif. , Feb. 5, 2016 Amgen ... 5 th Annual Global Healthcare Conference at 9:15 a.m. ... York City . David W. Meline , executive ... at the conference. Live audio of the presentation can be ... , under Investors. A replay of the webcast will also ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some ... to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay ... and detoxifying the body. , A former motivational speaker, Perry A~ has since dedicated ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... greater than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth ... ”It is time to make a change in public health,” states Carole Baggerly, ...
(Date:2/8/2016)... ... ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal growth ... on February 10th. During this time, people can achieve better health, greater wealth, ... from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... US Sports ... Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, and ... and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and Education, ...
Breaking Medicine News(10 mins):